One critical aspect is the recent approval of KarXT for schizophrenia, which, although positive, was anticipated and thus unlikely to significantly affect the stock’s value. The drug’s labeling was ...
New revelations from the showdown between Novo Nordisk’s CEO and Bernie Sanders’ Senate health committee Tuesday; PhRMA’s legal victory in IRA case; the federal interest rate cut and anticipated ...